By Hendra Lukman 
Researchers at Duke University have identified a critical enzyme involved in iron regulation within multiple myeloma (MM) cancer cells, demonstrating that its inhibition not only leads to the demise of these malignant cells but also significantly amplifies the efficacy of current therapeutic interventions. This groundbreaking discovery, published on September 12 in the prestigious journal Blood, offers a promising new avenue for treating this persistent and often refractory blood cancer.
The Scourge of Multiple Myeloma
Multiple myeloma is a complex and currently incurable cancer that originates from plasma cells, a vital component of the immune system responsible for producing antibodies to combat infections. In MM, these plasma cells undergo malignant transformation, accumulating uncontrollably within the bone marrow. This proliferation of cancerous cells crowds out healthy blood-forming cells, disrupting the production of essential blood components. Furthermore, MM cells often secrete excessive amounts of abnormal antibodies, which can lead to a cascade of debilitating health issues, including a compromised immune system, damage to vital organs like the kidneys, and the development of painful bone lesions.
Globally, multiple myeloma accounts for a substantial proportion of all blood cancer diagnoses, representing nearly 10 percent. While significant advancements have been made in developing targeted therapies to manage the disease, the clinical landscape is increasingly challenged by rising incidences of symptom relapse and the emergence of drug-resistant forms of the cancer. This persistent threat underscores the urgent need for innovative treatment strategies that can overcome current therapeutic limitations.
Unraveling the Mystery of Ferroptosis Suppression
The precise etiology of multiple myeloma remains an area of active investigation. However, a consistent observation in MM research has been the frequent suppression of a natural cellular process known as ferroptosis. Ferroptosis is a form of programmed cell death characterized by the accumulation of excess iron within cells, leading to oxidative damage to lipid membranes and subsequent cell disintegration. In healthy cells, this regulated process is crucial for maintaining cellular homeostasis. Conversely, in cancer cells, the suppression of ferroptosis allows them to survive and proliferate even under conditions of high iron levels that would typically prove toxic.
Mikhail Nikiforov, a professor of pathology and biomedical engineering at Duke University and a lead author on the study, articulated the perplexing nature of this phenomenon. "Cancer cells live like there is no tomorrow," he stated. "They accumulate iron at levels that would normally be toxic and tear cells apart, but that wasn’t what we observed. Instead, these cancer cells adapted to resist the type of cell death triggered by iron overload, and the mechanisms behind this suppression were largely unknown."
Identifying the Key Regulator: STK17B
For years, researchers have sought to elucidate the molecular underpinnings of this ferroptosis resistance. Nikiforov and his multidisciplinary team at Duke have now pinpointed a critical enzyme, kinase STK17B, as the primary culprit responsible for suppressing ferroptosis in multiple myeloma cells. STK17B, traditionally recognized for its roles in regulating cell death pathways and T-cell activation, was found by the Duke researchers to play a crucial role in maintaining cellular iron balance. They discovered that STK17B exerts its influence by modulating the expression of proteins that either promote (pro-ferroptotic) or inhibit (anti-ferroptotic) ferroptosis.
The significance of STK17B’s role in MM pathogenesis is further underscored by its association with patient outcomes. "Elevated levels of STK17B are associated with poor overall survival in MM patients," Nikiforov explained. "STK17B expression is also especially pronounced in relapsed cases of the disease, underscoring its role in therapy resistance." This correlation highlights STK17B as not only a key player in the cancer’s survival but also a potential indicator of treatment challenges.
A Novel Therapeutic Approach: Inhibiting STK17B
Building upon their identification of STK17B, the Duke team collaborated with Timothy Willson, the Harold Kohn Distinguished Professor in Open Science Drug Discovery at the UNC Eshelman School of Pharmacy, who developed a novel compound designed to inhibit STK17B. By targeting and blocking the enzymatic activity of STK17B, the researchers were able to disrupt its control over intracellular iron accumulation. This disruption effectively reactivated the dormant ferroptosis pathway within the MM cells, triggering their self-destruction.
Crucially, the study revealed a synergistic effect when STK17B inhibition was combined with conventional MM therapies. The researchers observed that the cancer cells, previously resistant to treatment, became significantly more susceptible to existing therapeutic agents when STK17B was suppressed. This suggests that inhibiting STK17B could serve as an adjuvant therapy, enhancing the effectiveness of current treatment regimens and potentially overcoming acquired resistance.
Preclinical Validation and Promising Results
To validate their findings in a living system, Nikiforov’s team conducted preclinical trials using an orally administered version of the STK17B inhibitor in mouse models of multiple myeloma. The results were highly encouraging. The compound successfully induced ferroptosis in the cancer cells by increasing their iron uptake, a key mechanism in reactivating the cell death pathway. Furthermore, this intervention led to a significant reduction in tumor growth within the treated mouse models.
"These findings establish that STK17B is a critical safeguard protecting MM cells from the toxic consequences of their iron independence," Nikiforov emphasized. "Inhibiting this kinase holds much promise as a therapeutic strategy." The ability of an orally administered compound to directly induce cancer cell death and reduce tumor burden in a preclinical setting represents a significant step forward in the development of new MM treatments.
Future Directions and Broader Implications
The implications of this research extend beyond the immediate treatment of multiple myeloma. The Duke team is actively pursuing the next steps in translating these findings into a clinical reality. They are exploring ways to optimize the formulation of the STK17B inhibitor for improved delivery and efficacy. In recognition of the therapeutic potential, the team has filed a provisional patent based on their discoveries, with the ultimate goal of commercializing this novel therapy.
Furthermore, the researchers are keen to investigate the broader applicability of their findings to other forms of cancer. Many other malignancies are known to exhibit resistance to ferroptosis, a characteristic that often contributes to their aggressive nature and refractoriness to treatment. "Many other types of cancer cells are also resistant to ferroptosis," Nikiforov noted. "We’re curious to see how this inhibitor could improve therapies for other tumors outside of multiple myeloma." This potential to address a fundamental mechanism of cancer resistance across diverse tumor types suggests that STK17B inhibition could represent a paradigm shift in cancer therapy.
A Collaborative Effort Fueled by Significant Investment
This pioneering research was made possible through substantial support from various national and institutional funding bodies, underscoring the collaborative and well-resourced nature of modern scientific inquiry. Key financial contributions came from the National Institutes of Health (NIH) and the National Cancer Institute (NCI) through grants NCI R01CA264984 (awarded to M.A.N.), NCI R01CA267275 and 17R21CA280499 (awarded to Y. K.), and NHLBI R01HL168492 (awarded to E.A.L.). The Duke Cancer Institute (NCI P30CA014236) also provided crucial support, alongside funding from the Paula and Rodger Riney Foundation (L.H.B.).
Additional support was provided by the Structural Genomics Consortium (SGC), a registered charity (no: 1097737) that benefits from significant investment from pharmaceutical and biotechnology companies including Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada, through the Ontario Genomics Institute [OGI-196], the EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (operating as EMD in Canada and the US), Pfizer, and Takeda. The NIH Illuminating the Druggable Genome grant 1U24DK116204-01 also contributed funding to this project, highlighting the broad scientific ecosystem that underpins such impactful discoveries. This extensive network of support signifies the recognized importance and potential of this research in advancing cancer treatment.
